High doses become routine patient care even when they make patients so ill that they skip doses or stop taking the drugs.
Tesla disclosed last month that it expects to book more than $350 million in costs in the second quarter for the mass layoffs ...
Amgen (NASDAQ: AMGN) is one of the top drugmakers in the world, with a market value north of $140 billion. The company has been expanding its business via acquisitions in recent years as it looks ...
Google fired around 200 employees and relocated some of the jobs overseas — the latest sign of a long-running effort by the ...
An image of a chain link. It symobilizes a website link url. Copy Link A new experimental weight-loss drug helped spark a 16% rally in Amgen stock on Friday. The pharmaceutical giant reported ...
Amgen's shares surged after management's earnings call comments about the phase 2 trial of obesity candidate MariTide. These comments and previous phase 2 data point to the increasing possibility ...
Amgen plans to seek European regulatory approval for the sale of its blockbuster Tepezza treatment for thyroid eye disease. The Thousand Oaks, Calif., biotechnology company on Friday said it is ...
In this edition of Week in Review (WiR), we recap Google's recent layoffs -- and Tesla's -- and the UnitedHealthcare hacks.
Fueled by upbeat management comments on an experimental obesity treatment, Amgen’s stock was on pace early Friday for its best day since 2009 — and analysts see more gains ahead as the company ...
Amgen's acquisition of Horizon Therapeutics has made it a major player in the rare disease space, with potential for long-term shareholder return. The company has key pipeline milestones in 2024 ...